CCT128930 - CAS 885499-61-6
Catalog number: 885499-61-6
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C18H20ClN5
Molecular Weight:
341.8379
COA:
Inquire
Targets:
Akt
Description:
CCT128930 is a novel ATP-competitive AKT inhibitor discovered using fragment- and structure-based approaches. It is a potent, advanced lead pyrrolopyrimidine compound exhibiting selectivity for AKT over PKA, achieved by targeting a single amino acid difference. CCT128930 exhibited marked antiproliferative activity and inhibited the phosphorylation of a range of AKT substrates in multiple tumor cell lines in vitro, consistent with AKT inhibition.
Synonyms:
CCT128930; CCT-128930; CCT 128930
MSDS:
Inquire
InChIKey:
RZIDZIGAXXNODG-UHFFFAOYSA-N
InChI:
InChI=1S/C18H20ClN5/c19-14-3-1-13(2-4-14)11-18(20)6-9-24(10-7-18)17-15-5-8-21-16(15)22-12-23-17/h1-5,8,12H,6-7,9-11,20H2,(H,21,22,23)
Canonical SMILES:
C1CN(CCC1(CC2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4
Current Developer:
Cancer Research UK Centre for Cancer Therapeutics
1.CCT128930 induces cell cycle arrest, DNA damage, and autophagy independent of Akt inhibition.
Wang FZ1, Chang ZY2, Fei HR3, Yang MF4, Yang XY4, Sun BL5. Biochimie. 2014 Aug;103:118-25. doi: 10.1016/j.biochi.2014.04.008. Epub 2014 May 1.
PI3K/Akt/mTOR pathway plays an important role in tumor progression and anti-cancer drug resistance. The aim of the present study is to determine the antitumor effect of CCT128930, a novel small molecule inhibitor of Akt, in the HepG2 hepatoma cancer cells. Our results showed that at low concentrations, CCT128930 increased, but not inhibited, the phosphorylation of Akt in HepG2 and A549 cells. CCT128930 inhibited cell proliferation by inducing cell cycle arrest in G1 phase through downregulation of cyclinD1 and Cdc25A, and upregulation of p21, p27 and p53. A higher dose (20 μM) of CCT128930 triggered cell apoptosis with activation of caspase-3, caspase-9, and PARP. Treatment with CCT128930 increased phosphorylation of ERK and JNK in HepG2 cells. CCT128930 activated DNA damage response of HepG2 cell characterized by phosphorylation of H2AX, ATM (ataxia-telangiectasia mutated), Chk1 and Chk2. Upon exposure to CCT128930 at a higher concentration, HepG2 cells exhibited autophagy was accompanied by an increase the levels of LC3-II and Beclin-1.
2.Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930.
Yap TA1, Walton MI, Hunter LJ, Valenti M, de Haven Brandon A, Eve PD, Ruddle R, Heaton SP, Henley A, Pickard L, Vijayaraghavan G, Caldwell JJ, Thompson NT, Aherne W, Raynaud FI, Eccles SA, Workman P, Collins I, Garrett MD. Mol Cancer Ther. 2011 Feb;10(2):360-71. doi: 10.1158/1535-7163.MCT-10-0760. Epub 2010 Dec 29.
AKT is frequently deregulated in cancer, making it an attractive anticancer drug target. CCT128930 is a novel ATP-competitive AKT inhibitor discovered using fragment- and structure-based approaches. It is a potent, advanced lead pyrrolopyrimidine compound exhibiting selectivity for AKT over PKA, achieved by targeting a single amino acid difference. CCT128930 exhibited marked antiproliferative activity and inhibited the phosphorylation of a range of AKT substrates in multiple tumor cell lines in vitro, consistent with AKT inhibition. CCT128930 caused a G(1) arrest in PTEN-null U87MG human glioblastoma cells, consistent with AKT pathway blockade. Pharmacokinetic studies established that potentially active concentrations of CCT128930 could be achieved in human tumor xenografts. Furthermore, CCT128930 also blocked the phosphorylation of several downstream AKT biomarkers in U87MG tumor xenografts, indicating AKT inhibition in vivo. Antitumor activity was observed with CCT128930 in U87MG and HER2-positive, PIK3CA-mutant BT474 human breast cancer xenografts, consistent with its pharmacokinetic and pharmacodynamic properties.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Akt Products


CAS 612847-09-3 AKT inhibitor VIII

AKT inhibitor VIII
(CAS: 612847-09-3)

Akt Inhibitor VIII is a cell-permeable quinoxaline compound that has been shown to potently, selectively, allosterically, and reversibly inhibit Akt1, Akt2, and...

CAS 902779-59-3 FPA 124

FPA 124
(CAS: 902779-59-3)

FPA 124 is an Akt/PKB inhibitor (IC50 = 100 nM) that inhibits cell proliferation in various cancer cell lines in vitro and decreases NF-κB activity and tumor lo...

CAS 342777-54-2 LM22B-10

LM22B-10
(CAS: 342777-54-2)

LM22B-10 is an activator of TrkB/TrkC neurotrophin receptor, which activates hippocampal and striatal TrkB and TrkC, and their downstream signaling, and increas...

CAS 885499-61-6 CCT128930

CCT128930
(CAS: 885499-61-6)

CCT128930 is a novel ATP-competitive AKT inhibitor discovered using fragment- and structure-based approaches. It is a potent, advanced lead pyrrolopyrimidine co...

CAS 171783-05-4 Crosstide

Crosstide
(CAS: 171783-05-4)

Crosstide, a peptide analog of glycogen synthase kinase α/β fusion protein sequence, acts as a substrate for Akt (PKB) (Km=4µM) and is useful in phosphocellulos...

CAS 1004990-28-6 PF-AKT400

PF-AKT400
(CAS: 1004990-28-6)

PF-AKT400 is an APT competitor inhibitor of AKR kinase. This compound was first described as compound 42 in J. Med. Chem. 2010, 53, 4615–4622 by a group of Pfi...

LY-3023414
(CAS: 1386874-06-1)

LY3023414, a quinoline derivative, has been found to be a PI3Kα and mTOR inhibitor that could influence cell proliferation and cycle of tumor cells. It was just...

CAS 893422-47-4 Akt1 and Akt2-IN-1

Akt1 and Akt2-IN-1
(CAS: 893422-47-4)

Akt1 and Akt2-IN-1 is an allosteric inhibitor of Akt1 and Akt2 with the IC50 of 3.5 nM and 42 nM respectively. It has potent and balanced activity. It is depend...

Chemical Structure

CAS 885499-61-6 CCT128930

Quick Inquiry

Verification code

Featured Items